Physician profile
Trisha Dee Werner
NPI 1851336481
$1,746.68
in general payments reported to CMS, 2019-2025
14 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.49 · 2020: $26.89 · 2021: $123 · 2022: $336 · 2023: $563 · 2024: $203 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $358.38 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $291.84 | 2019-2025 | Tryptyr, Precision7, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $271.44 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $125.00 | 2023 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $123.39 | 2021 | |
| Glaukos Corporation | $120.68 | 2023 | |
| Sun Pharmaceutical Industries INC. | $110.13 | 2022-2025 | Cequa |
| Apellis Pharmaceuticals, INC. | $106.49 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $106.47 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Genzyme Corporation | $50.00 | 2025 | |
| Abbvie INC. | $26.80 | 2023 | Lumigan, Alphagan P, Vuity |
| Novartis Pharmaceuticals Corporation | $22.25 | 2023 | |
| Shire North American Group INC | $20.90 | 2019 | |
| Coopervision INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.